{
    "SPADE_UN_25931": {
        "Sequence Information": {
            "Peptide Name": "Hemiasterlin SPA 110, Taltobulin, HTI-286",
            "Sequence": "XXX",
            "Sequence Length": 3,
            "Biological Activity": [
                "Anticancer"
            ],
            "Binding Target": "1. Cytoplasmic Protein",
            "Source": "",
            "Gene": "",
            "PDB ID": "",
            "UniProt Entry": [],
            "Literature": [
                {
                    "Title": "Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues.",
                    "Pubmed ID": "12608848",
                    "Reference": "J Nat Prod. 2003;66:183-199",
                    "Author": "Nieman JA, Coleman JE, Wallace DJ, Piers E, Lim LY, Roberge M, Andersen RJ",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/12608848"
                },
                {
                    "Title": "Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin",
                    "Pubmed ID": "18240145",
                    "Reference": "Int J Cancer. 2008;122:2368-2376",
                    "Author": "Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/18240145"
                }
            ],
            "SPADE ID": "SPADE_UN_25931",
            "Similar Sequences": [],
            "Hemolytic Activity": "",
            "Target Organism": "Human breast adenocarcinoma MCF-7(IC50=0.00009µM),Human prostate adenocarcinoma LNCaP(IC50=0.00065±0.0003µM),Human prostate carcinoma C4-2(IC50=0.0017±0.0009µM),Human prostate adenocarcinoma PC-3(IC50=0.0019±0.0007µM),Human prostate adenocarcinoma PC-3dR(IC50=0.0046±0.0003µM)"
        }
    }
}